Synergy Pharmaceuticals Inc fka SGYPQ

[Dcharpool]

https://www.synergy-pharmaceuticals.com/
Herpes cure and constipation aid. Same company correct? Coming back to life or what?

[nsomniyak]

Speaking of smoke, can we have some of what you've been smoking?

[biotech_researcher]

Good luck with that..

[Opti Mist]

did you mean to highlight something in all that?

Or do we have to read and guess?

LOL

Opti

[Dcharpool]

18-14010-jlg Doc 739 Filed 05/01/19
SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP
Lisa Laukitis
Christine A. Okike
Four Times Square
New York, New York 10036-6522 Telephone: [phone]
Fax: [phone]
– and –
Ron E. Meisler (admitted pro hac vice) Christopher M. Dressel (admitted pro hac vice) Jennifer Madden (admitted pro hac vice)
155 North Wacker Drive
Chicago, Illinois 60606-1720
Telephone: [phone]
Fax: [phone]
Counsel to Debtors
and Debtors-in-Possession
UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK
In re
SYNERGY PHARMACEUTICALS INC., et al.,
Entered 05/01/19 13:37:53 Main Document Pg 1 of 5
TOGUT, SEGAL & SEGAL LLP Albert Togut
Neil M. Berger
Kyle J. Ortiz
One Penn Plaza
Suite 3335
New York, New York 10119 Telephone: [phone] Fax: [phone]
Debtors.1
Chapter 11
Case No. 18-14010 (JLG) Jointly Administered Related Docket No. 712 & 713
NOTICE OF (I) ENTRY OF FINDINGS OF FACT, CONCLUSIONS OF LAW AND ORDER CONFIRMING MODIFIED FOURTH AMENDED JOINT PLAN OF REORGANIZATION OF SYNERGY PHARMACEUTICALS INC. AND ITS DEBTOR AFFILIATE AND (II) OCCURRENCE OF EFFECTIVE DATE
1
The Debtors in these chapter 11 cases, along with the last four digits of their respective tax identification numbers, are as follows: Synergy Pharmaceuticals Inc. (5269); Synergy Advanced Pharmaceuticals, Inc. (4596). The address of the Debtors’ corporate headquarters is 620 Lee Road, Chesterbrook, Pennsylvania 19087.

18-14010-jlg Doc 739 Filed 05/01/19 Entered 05/01/19 13:37:53 Main Document Pg 2 of 5
PLEASE TAKE NOTICE OF THE FOLLOWING:
1. Plan Confirmation. On April 25, 2019, this Court entered an order (the “Confirmation Order”) confirming the Modified Fourth Amended Joint Plan of Reorganization of Synergy Pharmaceuticals Inc. and Its Debtor Affiliate (the “Plan”) [Docket No. 713].2
2. Copies of Plan and Confirmation Order. The Confirmation Order included the Plan as Exhibit A. The Confirmation Order, the Plan, and the other documents filed in these cases, are available free of charge at https://cases.primeclerk.com/Synergy/Home-DocketInfo or for a nominal fee at https://ecf.nysb.uscourts.gov/ (with use of a PACER account).
3. Effective Date. On May 1, 2019, the Effective Date of the Plan occurred. All conditions precedent to the Effective Date set forth in Section 10.01 of the Plan have been satisfied or waived.
4. Professional Claims.
a. Final Fee Applications. All final requests for payment of Professional Claims must be filed no later than 45 days after the Effective Date. After notice and a hearing in accordance with the procedures established by the Bankruptcy Code, the Bankruptcy Rules and prior orders of the Bankruptcy Court, the Allowed amounts of such Professional Claims shall be determined by the Bankruptcy Court.
b. Post-Effective Date Retention. Upon the Effective Date, any requirement that Professionals comply with sections 327 through 331 of the Bankruptcy Code in seeking retention or compensation for services rendered after the Effective Date shall terminate, and the Plan Administrator shall be permitted to employ and pay professionals in its discretion.
5. Administrative Claims. Except as otherwise provided in the Plan and as set forth in Section 2.02 and Section 2.03 of the Plan, all requests for payment of an Administrative Claim must be filed, in substantially the form of the Administrative Claim Request Form contained in the Plan Supplement, with the Claims and Solicitation Agent and served on counsel for the Liquidating Debtor, the Plan Administrator and the Litigation Trustee, no later than the Administrative Claim Bar Date, which shall be 30 days after the Effective Date. Any request for payment of an Administrative Claim pursuant to Section 2.01 of the Plan that is not timely filed and served shall be Disallowed automatically without the need for any objection from the Liquidating Debtor, the Plan Administrator or the Litigation Trustee. The Plan Administrator (and the Litigation Trustee, as applicable, in accordance with Section 5.11(b) of the Plan) may settle any Administrative Claim without further Bankruptcy Court approval. In the event that the Liquidating Debtor or the Plan Administrator (and the Litigation Trustee, as applicable, in accordance with Section 5.11(b) of the Plan) object to an Administrative Claim and there is no settlement, the Bankruptcy Court shall determine the Allowed amount of such Administrative Claim.
2
if not used therein, in the Plan.
Capitalized terms used but not defined herein have the meanings assigned to them in the Confirmation Order or,
2

18-14010-jlg Doc 739 Filed 05/01/19 Entered 05/01/19 13:37:53 Main Document Pg 3 of 5
6. Claims Objection Deadline. “Claims Objection Deadline” means the later of (a) (i) as to Rejection Damages Claims, the first Business Day that is at least 180 days after such Rejection Damages Claim is timely filed pursuant to Section 6.01(b) of the Plan; (ii) as to late- filed proofs of Claim, the first Business Day that is at least 60 days after a Final Order is entered deeming the late-filed Claim timely filed; and (iii) as to all other Claims the first Business Day that is at least one year after the Effective Date; or (b) such later date as may be established by the Bankruptcy Court by motion of the Litigation Trustee.
7. Executory Contracts and Unexpired Leases to Be Rejected. Except as otherwise provided in the Plan, upon the occurrence of the Effective Date, each Executory Contract and Unexpired Lease shall be deemed rejected in accordance with, and subject to, sections 365 and 1123 of the Bankruptcy Code as of the Effective Date, unless any such Executory Contract or Unexpired Lease: (i) is listed on the Schedule of Assumed Executory Contracts contained in the Plan Supplement; (ii) has been previously assumed by the Debtors by Final Order of the Bankruptcy Court or has been assumed by the Debtors by order of the Bankruptcy Court as of the Effective Date, which order becomes a Final Order after the Effective Date; (iii) is the subject of a motion to assume pending as of the Effective Date; (iv) is an Insurance Contract; or (v) is otherwise assumed pursuant to the terms in the Plan. The Confirmation Order constitutes an order of the Bankruptcy Court approving such rejections pursuant to sections 365 and 1123 of the Bankruptcy Code as of the Effective Date. Counterparties to Executory Contracts or Unexpired Leases that are deemed rejected as of the Effective Date shall have the right to assert any Claim on account of the rejection of such Executory Contracts or Unexpired Leases subject to compliance with the requirements in the Plan.
8. Executory Contracts to Be Assumed. Except as otherwise provided in the Plan, upon the occurrence of the Effective Date, each Executory Contract that is listed on the Schedule of Assumed Executory Contracts contained in the Plan Supplement, shall be deemed assumed, in accordance with, and subject to, sections 365 and 1123 of the Bankruptcy Code as of the Effective Date. The Confirmation Order will constitute an order of the Bankruptcy Court approving such assumptions, pursuant to sections 365 and 1123 of the Bankruptcy Code as of the Effective Date. To the extent any provision in any Executory Contract assumed pursuant to the Plan (including any “change of control” provision) restricts or prevents, or purports to restrict or prevent, or is breached or deemed breached by, the Liquidating Debtor’s assumption of such Executory Contract, then such provision shall be deemed modified such that the transactions contemplated by the Plan will not entitle the non-Debtor party thereto to terminate such Executory Contract or to exercise any other default-related rights with respect thereto. Each Executory Contract assumed pursuant to Article VI of the Plan will revest in and be fully enforceable by the Plan Administrator on behalf of the Liquidating Debtor, except as modified by the provisions of the Plan, any order of the Bankruptcy Court authorizing and providing for its assumption, or applicable law.
9. Rejection Damages Bar Date. Unless otherwise provided by a Bankruptcy Court order, any proofs of Claim asserting Claims arising from the rejection of the Executory Contracts and Unexpired Leases pursuant to the Plan or otherwise must be filed with the Claims and Solicitation Agent no later than 30 days after the later of the Effective Date, the effective date of rejection, or the date notice of such rejection is transmitted by the Debtors or the Plan
3

18-14010-jlg Doc 739 Filed 05/01/19 Entered 05/01/19 13:37:53 Main Document Pg 4 of 5
Administrator, as applicable, to the counterparty to such Executory Contract or Unexpired Lease. Any proofs of Claim arising from the rejection of Executory Contracts or Unexpired Leases that are not timely filed shall be Disallowed automatically and forever barred, estopped, and enjoined from assertion and shall not be enforceable against the Debtors or the Liquidating Debtor, without the need for any objection by the Litigation Trustee or any further notice to or action, order, or approval of the Bankruptcy Court, and any Claim arising out of the rejection of the Executory Contract or Unexpired Lease shall be deemed fully satisfied and released, notwithstanding anything in the Schedules or a proof of Claim to the contrary. All Allowed Claims arising from the rejection of Executory Contracts and Unexpired Leases shall be classified as General Unsecured Claims.
10. Post-Effective Date Notice Pursuant to Bankruptcy Rule 2002. After the Effective Date, to continue to receive notice of documents pursuant to Bankruptcy Rule 2002, all creditors and other parties in interest (except those listed in the Confirmation Order) must file a renewed notice of appearance requesting receipt of documents pursuant to Bankruptcy Rule 2002.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
4

18-14010-jlg Doc 739 Filed 05/01/19 Entered 05/01/19 13:37:53 Main Document Pg 5 of 5
Dated: New York, New York ? May 1, 2019 ? ?
? SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP ?
? /s/ Ron E. Meisler
? Lisa Laukitis
? Christine A. Okike
? Four Times Square
? New York, New York 10036-6522
? Telephone: [phone]
Fax: [phone]
– and –
? Ron E. Meisler (admitted pro hac vice)
? Christopher M. Dressel (admitted pro hac vice)
? Jennifer Madden (admitted pro hac vice)
? 155 North Wacker Drive
? Chicago, Illinois 60606-1720
? Telephone: [phone]
Fax: [phone]
– and –
TOGUT, SEGAL & SEGAL LLP Albert Togut
Neil M. Berger
Kyle J. Ortiz
One Penn Plaza
Suite 3335
New York, New York 10119 Telephone: [phone] Fax: [phone]
? Co-Counsel to Debtors and Debtors-in-Possession
5

[oich]

That would be fantastic but need to temper expectations without proof. If you’re interested you can read the latest motion on the docket for some background (link below). It looks like they set aside about .005 per share for equity (probably less when everything is settled). Also, equity gets share of litigation proceeds after unsecured and loans are paid off. Litigation can take years to resolve and no guarantee that there will be something left for equity but the fact that they already carved out some money for equity is a good sign.

https://cases.primeclerk.com/Synergy/Home-DownloadPDF?id1=MTEwNzcwNA==&id2=0

[KLstocks]

Really? I have 18k shares, so that would be amazing....

[Polack]

0.25-0.33 per share distribution pay out. SGYPQ

[420man]

This is exactly why I was wondering why traders were still buying this above .005. Never ceases to amaze me why people keep buying a stock just before the commons are canceled. Oh well.

[Renee]

SGYPQ: Bankruptcy PLAN effective. All shares cancelled.

FINRA deleted symbol:

https://otce.finra.org/otce/dailyList?viewType=Deletions

[420man]

248M OS divided by $1.375M = .0055 PS

[420man]

The Plan further provides that, on or immediately following the Effective Date thereof, (a) all equity interests in Synergy Pharmaceuticals will be deemed automatically cancelled, released, and extinguished; (b) the respective boards of directors of the Debtors shall be terminated and the members thereof shall be deemed to have resigned; (c) Synergy Advanced shall be merged with and into Synergy Pharmaceuticals, which shall be converted a Delaware limited liability company and thereafter continue to exist as the Liquidating Debtor.

[oich]

It may be due to the settlement regarding the plan changes between various parties including the equity committee, debtor, creditors committee etc. Check out page 8 of the doc. Seems to indicate they carved out a little money for equity.

https://cases.primeclerk.com/Synergy/Home-DownloadPDF?id1=MTA5Mjc3Ng==&id2=0

[tdeck]

Accumulation has taken hold, volume hasn't changed number of loose shares has IMO .009-.011 is as safe as a babe in its mothers arms to catch some obviously closer to .009 the better, it's percolating me thinks.

[albeeno]

Why is this up like this? Can't find much info on this stock

[tdeck]

I half filled my load 425K shares @ .009-.0107 looks like she is tightening up a little. We will see in the days to come.

[makinezmoney]

$SGYPQ: I was hoping for lower.... but its bouncing


Should've picked some up at the $0.009 level after all.


This has a good chance to bounce harder if this holds up now.

Should be on watch all day.



GO $SGYPQ

[tdeck]

What's up makin' you still thinking the same? Thanks for your input.

[althegambler]

who is ambio pharm and why would synergy owe them almost 1 mill. bucks. the latest docket is showing that deal to be expunged.

[althegambler]

if one goes back to docket 537 you can see what they are attempting here. let the IRs, FDA, SEC and the gov't. in general see that the hell has been going on here. the SEC should have stepped into this whole dam thing a long time ago.

[althegambler]

a new docket filed today. an appeal from the lawyers for the equity group representing the stockholders.

[althegambler]

in addition to the SEC also mentioned is IRS, FDA, Att: for Southern District of NY plus a few others. another thing I noticed counsel for the Debtors is the law firm of Skadden who has been mentioned in the Manafort debacle. CRG and the gang at SGYP might just be the naughty boys we suspect they are.

[DannyBSongs]

Is there any way to make money off this puppy?
Will shares be completely dilluted?
Will Bauch issue new shares?
Thanks in advance!

[althegambler]

I see where the meeting at the court for March 20 has been cancelled by the lawyers for Synergy but the equity group lawyers have changed it to April 9. I wonder what that is all about. Maybe they are not happy that the SEC, and others will be present. both of those dockets are showing up today.

[420man]

Damn...she's going down faster than I thought! Sub penny coming... Hope peeps reduced exposure!

[makinezmoney]

$SGYPQ: Collapse down to $0.003


I'll be waiting for you my DEAR.



GO $SGYPQ

[biotech_researcher]

Nope..

[makinezmoney]

$SGYPQ: Now at $0.02... waiting for an entry here


Looking to capitalize on this BK dump play.


Wait and Watch.



GO $SGYPQ

[enf1945]

is this up for bids yet ?

[Polack]

If you've read every SGYPQ PR, SEC Filing, and Court Doc, you know that only Trulance/Dolcanatide ("certain assets") were sold to Bausch. Assets SGYPQ retained to develop a new pipeline from are the Uroguanylin GI Platform and "Novel Guanylate Cyclase C Agonists" from patents 10,118,946 & 9,708,367:
"Detailed Description: The present invention is based upon the development of novel agonists of guanylate cyclase-C (GC-C). The agonists are plecanatide derivatives, analogs of uroguanylin, guanylin, lymphoguanylin and ST peptide and have superior properties such as higher activity or potency."
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=novel+guanylate+cyclase+C+%28GC-C%29+agonists&FIELD1=&co1=AND&TERM2=Synergy+Pharmaceuticals&FIELD2=&d=PTXT

[enf1945]

use the balance sheet in the court filings.

What do you see?
thanks

[enf1945]

so is there anything left for stockholders ?

[enf1945]

Being in Bankruptcy it should be no suprise it was delisted . Yet it drops 50% !
thing to look at now are the financial reports filed with the court.
They are here : https://cases.primeclerk.com/Synergy/Home-DocketInfo

Can anyone say if there is any residual value ?
10Q is now old, but not useless.

[Renee]

SGYP changed to SGYPQ:

https://otce.finra.org/otce/dailyList?viewType=Additions

[jonsmile]

Put a fork in this one sorry guys who ever was the last out turned off the lights

[420man]

https://ih.advfn.com/stock-market/NASDAQ/synergy-pharmaceuticals-inc-SGYP/stock-news/79432093/current-report-filing-8-k

[420man]

The big sell off EOD yesterday was by those in-the-know....

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147370070

[oich]

Yes looks like they shut down the common stock. Common stock is now relying on the equity committee to find value for commons. There was mention of there being potential value in one of their recent motions or replies, but it will take a very long time for them to settle everything.

[Opti Mist]

no bid or ask premarket.

Bid (Size)$ x
Ask (Size)$ x
52 Week Range –
P/Ex
EPS
Next Earnings Date–
Ex-Dividend Date–
Dividend Payable Date–
Dividend Yield/Amount% /

[biotech_researcher]

The problem is you are using the 10Q, which is a snap shot in time BEFORE bankruptcy. After bankruptcy, there is nothing left..

[jhnvtjll]

After everything's done, any chance this clean shell could do a reverse merger with a private company that wants to go public?

[iDeVos]

So you think they are selling basically all their assets to Bausch through BK proceedings and yet still have $83M in cash on hand?

No, $83M is cash plus other assets. According to court documents (see section 1.2 below); cash & cash equivalents ($45.6M) and account receivable ($9.2M) stay with Synergy, while inventory ($21.5M) and properties & equipments ($1.1M) will go to BHC.

Regarding to the total liabilities of $179M in the balance sheet, most will be covered by BHC (see section 1.3 below), like account payable ($11.2M) and even some of the $101M term loan. Because I think a portion of that loan was for Trulance development (see the text highlighted in section 1.3)

With all of these, there will be a significant amount of cash left after the transactions completed.

Again, link to the most recent 10-Q with the detailed balance sheet:
https://www.sec.gov/ix?doc=/Archives/edgar/data/1347613/000134761318000032/sgyp-20180930.htm



AMENDED AND RESTATED ASSET PURCHASE AGREEMENT
THIS AMENDED AND RESTATED ASSET PURCHASE AGREEMENT, dated as of January 4, 2019 (this “Agreement”), is made by and among Synergy Pharmaceuticals Inc., a Delaware corporation (the “Parent”), its wholly-owned subsidiary, Synergy Advanced Pharmaceuticals, Inc., a Delaware corporation (together with the Parent, in their capacities as debtors and debtors-in-possession, the “Sellers”), Bausch Health Companies Inc., a corporation organized under the laws of British Columbia, Canada (“BH”), and its wholly-owned subsidiary Bausch Health Ireland Limited, a private limited company organized under the laws of Ireland (the “Purchaser”). Each of the Sellers, BH and the Purchaser is referred to individually herein as a “party” and collectively as the “parties.” Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in Article IX.
WHEREAS, the Sellers are engaged in the business of, directly or indirectly, developing, making or having made, promoting, using, licensing and selling the Products (such business, as conducted by the Sellers as of the date hereof, the “Business”);
WHEREAS, the Sellers filed voluntary petitions for relief commencing cases (collectively, the “Chapter 11 Case”) under Chapter 11 of Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the Southern District of New York (the “Bankruptcy Court”) on December 12, 2018 (the “Petition Date”);
WHEREAS, the Purchaser desires to purchase and accept, and the Sellers desire to sell, convey, assign, transfer and deliver, or cause to be sold, conveyed, assigned, transferred and delivered, to the Purchaser, all of the Acquired Assets, and the Purchaser is willing to assume, and the Sellers desire to assign and delegate to the Purchaser, all of the Assumed Liabilities, all in the manner and subject to the terms and conditions set forth herein and in accordance with Sections 105, 363 and 365 of the Bankruptcy Code, subject to the Purchaser’s right to assign its rights and obligations hereunder to one of more of its Affiliates (such sale and purchase of the Acquired Assets and such assignment and assumption of the Assumed Liabilities, the “Acquisition”);
WHEREAS, the parties acknowledge and agree that the purchase by the Purchaser of the Acquired Assets, and the assumption by the Purchaser of the Assumed Liabilities, are being made at arm’s length and in good faith and without intent to hinder, delay or defraud creditors of the Sellers or their Affiliates;
WHEREAS, the parties entered into that certain asset purchase agreement (the “Original Asset Purchase Agreement”), dated as of December 11, 2018 (the “Execution Date”) and now desire to amend and restate the terms and provisions of the Original Asset Purchase in its entirety in accordance with and subject to the terms and conditions of this Agreement;
WHEREAS, the execution and delivery of this Agreement and the Sellers’ ability to consummate the transactions set forth in this Agreement are subject to, among other things, the entry of the Sale Order under, inter alia, Sections 363 and 365 of the Bankruptcy Code; and
WHEREAS, the parties desire to consummate the proposed transaction as promptly as practicable after the Bankruptcy Court enters the Sale Order.

NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree to amend and restate the Original Asset Purchase Agreement in its entirety as follows; provided that this Agreement and the rights and obligations of the parties hereunder shall continue to be effective as of the Execution Date and references herein to the date of this Agreement or the date hereof or similar phrases shall be deemed to be the Execution Date:

ARTICLE I
THE ACQUISITION
Section 1.1. Acquired Assets. On the terms and subject to the conditions set forth in this Agreement and, subject to approval of the Bankruptcy Court, pursuant to Sections 105, 363 and 365 of the Bankruptcy Code, at the Closing, the Sellers shall sell, assign, transfer, convey and deliver, or cause to be sold, assigned, transferred, conveyed and delivered, to the Purchaser, and the Purchaser shall purchase and accept from the Sellers, free and clear of all Encumbrances of any and every kind, nature and description, other than Permitted Post-Closing Encumbrances, all right, title and interest of the Sellers in, to or under all of the rights, properties and assets of the Sellers of every kind and description, wherever located, real, personal, or mixed, tangible or intangible, to the extent owned, leased, licensed, used or held for use in or relating to the Business, as the same shall exist on the Closing Date, other than the Excluded Assets (collectively, the “Acquired Assets”), including all right, title and interest of the Sellers in, to and under the Acquired Assets that are listed or described below:
(a) other than as set forth in Section 1.2(k), all of the Sellers’ accounts receivable (but excluding any noncurrent accounts receivable) and any other receivables of the Sellers, in each case as of the Closing Date;
(b) all credits, claims for refunds, deposits for the benefit of third parties and prepaid expenses (other than (x) all credits, refunds, deposits and prepaid amounts with respect to Excluded Taxes and (y) to the extent not in respect of Taxes, all credits, refunds, deposits and prepaid amounts that relate primarily to any of the Excluded Assets or the Excluded Liabilities);
(c) the Contracts listed, described or otherwise identified on Section 1.1(c) of the Seller Disclosure Schedule, as such schedule may be amended from time to time pursuant to Section 1.5(e) (such Contracts, the “Assigned Contracts”) and the rights thereunder;
(d) all raw materials, work-in-process, finished goods, supplies (including clinical drug supplies), samples (including samples held by sales representatives), components, packaging materials, and other inventories to which the Sellers have title that are in the possession of the Sellers or any third party and used or held for use in connection with any Product or an Acquired Asset (collectively, “Inventory”);
(e) all machinery, equipment, apparatus, appliances, implements, computers and computer-related hardware, files, documents, network and internet and information technology systems-related equipment and all other tangible personal and intangible property including all other fixed assets and items of personal property used or held for use in the conduct of the Business or otherwise owned by the Sellers, which shall include all servers and computers used to develop and maintain code in various operating environments, all development environment and software currently residing on such computers;
(f) all Seller Intellectual Property, including Seller Registered Intellectual Property (including the items listed on Section 1.1(f) of the Seller Disclosure Schedule) and all of the Sellers’ rights therein, including all rights to sue for and recover and retain damages for present and past infringement thereof and, in the case of Trademarks that are Seller Intellectual Property, all goodwill appurtenant thereto;
(g) all rights under non-disclosure or confidentiality, invention and Intellectual Property assignment agreements executed for the benefit of the Sellers with current or former employees, consultants or contractors of the Sellers or with third parties (in the case of rights under the Parent Confidentiality Agreement, solely to the extent provided in Section 5.15(b));
(h) all Books and Records, other than Retained Books and Records;
(i) to the extent transferable, all Permits and all pending applications therefor;
(j) other than as set forth in Section 1.2(b) or Section 1.2(i), to the extent transferable, all insurance policies and rights thereunder;
(k) all goodwill and other intangible assets associated with the Business, the Acquired Assets and the Assumed Liabilities;
(l) all rights, claims, rebates, refunds, causes of action, actions, suits or proceedings, hearings, audits, rights of recovery, rights of setoff, rights of recoupment, rights of reimbursement, rights of indemnity or contribution and other similar rights (known and unknown, matured and unmatured, accrued or contingent, regardless of whether such rights are currently exercisable) against any Person, including all warranties, representations, guarantees, indemnities and other contractual claims (express, implied or otherwise) to the extent related to the Business, the Acquired Assets or the Assumed Liabilities (including any claims for past infringement or misappropriation) (without duplication of the rights, claims or causes of action of any of the Sellers set forth in Sections 1.2(f), 1.2(g), 1.2(h), 1.2(i), 1.2(j) and 1.2(k));
(m) all avoidance claims or causes of action available to the Sellers under Chapter 5 of the Bankruptcy Code (including Sections 544, 545, 547, 548, 549, 550 and 553) or any similar actions under any other applicable Law (collectively, “Avoidance Actions”) against the following (collectively, the “Designated Parties”): (i) any of the Sellers’ vendors, suppliers, customers or trade creditors with whom the Purchaser continues to conduct business in regard to the Acquired Assets after the Closing, (ii) any of the Sellers’ counterparties under any licenses of Intellectual Property that are Assigned Contracts or counterparties under any other Assigned Contracts and (iii) any Affiliates of any of the Persons listed in clauses (i) and (ii); provided, however, that it is understood and agreed by the parties that the Purchaser will not pursue or cause to be pursued any Avoidance Actions against any of the Designated Parties other than as a defense (to the extent permitted under applicable Law) against any claim or cause of action raised by such Designated Party;
(n) all proceeds of any settlement from and after the date hereof through the Closing of any claims, counterclaims, rights of offset or other causes of action of any of the Sellers against any of the Designated Parties;
(o) any and all insurance proceeds, condemnation awards or other compensation in respect of loss or damage to any of the Acquired Assets to the extent occurring on or after the date hereof, and all rights and claim of the Sellers to any such insurance proceeds, condemnation awards or other compensation not paid by the Closing; and
(p) all security and utility deposits, credits, allowance or other assets, or charges, setoffs, prepaid expenses, and other prepaid items related to the Acquired Assets.

EXCEPT AS EXPRESSLY SET FORTH IN ARTICLE III OF THIS AGREEMENT OR ANY ANCILLARY DOCUMENT DELIVERED BY ANY SELLER PURSUANT TO THIS AGREEMENT (I) THE SELLERS MAKE NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, AT LAW OR IN EQUITY, RELATING TO THE BUSINESS, THE ACQUIRED ASSETS OR THE ASSUMED LIABILITIES, INCLUDING ANY REPRESENTATION OR WARRANTY AS TO VALUE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR FOR ORDINARY PURPOSES, OR ANY OTHER MATTER, (II) THE SELLERS MAKE NO, AND HEREBY DISCLAIM ANY, OTHER REPRESENTATION OR WARRANTY REGARDING THE BUSINESS, THE ACQUIRED ASSETS OR THE ASSUMED LIABILITIES, AND (III) THE ACQUIRED ASSETS AND THE ASSUMED LIABILITIES ARE CONVEYED ON AN “AS IS, WHERE IS” BASIS AS OF THE CLOSING, AND THE PURCHASER SHALL RELY UPON ITS OWN EXAMINATION THEREOF. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, EXCEPT AS EXPRESSLY SET FORTH IN ARTICLE III OF THIS AGREEMENT OR ANY ANCILLARY DOCUMENT DELIVERED BY ANY SELLER PURSUANT TO THIS AGREEMENT, THE SELLERS MAKE NO REPRESENTATION OR WARRANTY REGARDING ANY BUSINESS OTHER THAN THE BUSINESS, ANY ASSETS OTHER THAN THE ACQUIRED ASSETS OR ANY LIABILITIES OTHER THAN THE ASSUMED LIABILITIES, AND NONE SHALL BE IMPLIED AT LAW OR IN EQUITY.

Section 1.2. Excluded Assets. Notwithstanding anything contained in this Agreement to the contrary, the Acquired Assets shall not include any of the following (collectively, the “Excluded Assets”):
(a) all Cash, other than any and all rights of the Sellers in and to any restricted cash, security deposits, escrow deposits and cash collateral (including cash collateral given to obtain or maintain letters of credit and cash drawn or paid on letters of credit) that primarily relate to the Assumed Liabilities or the Acquired Assets; provided, however, that any Encumbrance created under the Prepetition Credit Agreement or the Final DIP Order shall not, in and of itself, render any Cash restricted for purposes of this paragraph and such Cash shall be an “Excluded Asset”;
(b) all current and prior director and officer or similar fiduciary or errors and omissions insurance policies and all rights thereunder and all proceeds thereof;
(c) any credits, refunds, deposits and prepaid amounts with respect to Excluded Taxes;
(d) any shares of capital stock or other equity interests of any Seller or any Affiliate thereof or any securities convertible into, exchangeable or exercisable for shares of capital stock or other equity interests of any Seller or any Affiliate thereof;
(e) Retained Books and Records;
(f) (i) any avoidance actions against any Person other than any of the Designated Parties, (ii) any proceeds of any settlement from and after the date hereof through the Closing of any claims, counterclaims, rights of offset or other causes of action of any of the Sellers against any Person other than any Designated Party, and (iii) all claims or causes of action of the Sellers other than those identified in Section 1.1(l) and Section 1.1(m);
(g) all rights, claims or causes of action of any Seller arising under this Agreement, the Ancillary Documents or the Confidentiality Agreement or arising under the Parent Confidentiality Agreements (to the extent not assigned to the Purchaser pursuant to Section 5.15(b));
(h) all rights, claims or causes of action by or in the right of any of the Sellers against any current or former director or officer of any such Seller;
(i) all Benefit Plans, all assets of such Benefit Plans and all trust agreements, administrative service contracts, insurance policies and other Contracts related thereto and all rights of the Sellers with respect to any of the foregoing;
(j) all Contracts that are not Assigned Contracts, including the Contracts listed or described on Section 1.2(j) of the Seller Disclosure Schedule, which schedule may be modified in accordance with Section 1.5(e);
(k) all receivables, claims or causes of action that relate primarily to any of the Excluded Assets or the Excluded Liabilities, other than any receivables, claims or causes of action that relate to the Contracts set forth on Section 1.2(k) of the Seller Disclosure Schedule;
(l) any assets set forth on Section 1.2(l) of the Seller Disclosure Schedule;
(m) all leases, subleases or Contracts under which Sellers occupy any real property;
(n) all intercompany accounts receivable as to which any of the Sellers is an obligor or is otherwise responsible or liable and which are owed or payable to any of the Sellers; and
(o) all Contracts that are disclosed or required to be disclosed pursuant to Section 3.8 hereof.

Section 1.3. Assumed Liabilities. On the terms and subject to the conditions set forth in this Agreement, at the Closing, in consideration for the sale, assignment, conveyance, transfer and delivery of the Acquired Assets to the Purchaser, the Purchaser shall assume from the Sellers and agree to pay, perform and discharge, when due, in accordance with their respective terms and subject to the respective conditions thereof, only the following liabilities and obligations (of any nature or kind, and whether based in common law or statute or arising under written Contract or otherwise, known or unknown, fixed or contingent, accrued or unaccrued, liquidated or unliquidated, asserted or unasserted) of the Sellers (collectively, the “Assumed Liabilities”):
(a) except as expressly set forth herein, all liabilities and obligations arising from the ownership, possession or use of the Acquired Assets and the operation of the Business, in each case from and after the Closing, it being understood that liabilities and obligations arising from the ownership, possession or use of the Acquired Assets or the operation of the Business prior to the Closing (including the sale of Products by the Sellers and their Affiliates prior to the Closing) other than Cure Costs shall not constitute Assumed Liabilities regardless of when the obligation to pay such liabilities and obligations arises;
(b) all liabilities and obligations arising under the Assigned Contracts, arising after the Closing (other than Cure Costs);
(c) all Cure Costs;
(d) (i) all current accounts payable (and excluding any noncurrent accounts payable) as to which any of the Sellers is responsible or liable and which are owed by any of the Sellers as of the Closing, in each case to the extent such amounts are in respect of (1) manufacturing costs related to Inventory, but excluding any payables related to API (including related to any purchases of API pursuant to Section 5.23) which shall be deemed to be a Cure Cost, or (2) accrued liabilities as of the Closing Date for research and development related to the Products up to $312,000 and (ii) all claims related to or arising from rebates, coupon programs, chargebacks and credits;
(e) any liability in respect of royalty payments that initially become due and payable after the Closing Date and are due to third parties arising with respect to sales occurring before the Closing;
(f) claims related to or arising from returns or expirations of the Products to the extent arising after the Closing;
(g) all liabilities and obligations relating to the employment or termination of the Transferred Employees, solely to the extent arising after the Closing.
The transactions contemplated by this Agreement shall in no way expand the rights or remedies of any third party against the Purchaser or Sellers as compared to the rights and remedies that such third party would have had against Sellers absent the Chapter 11 Case had the Purchaser not assumed such Assumed Liabilities.

Section 1.4. Excluded Liabilities. Notwithstanding anything contained in this Agreement to the contrary, none of BH, the Purchaser or any Affiliate of either of the foregoing shall assume, be obligated to assume, be deemed to have assumed, or be obliged to pay, perform or otherwise discharge, and the Sellers shall be solely and exclusively liable with respect to, any liabilities or obligations (of any nature, and whether based in common law or statute or arising under written Contract or otherwise, known or unknown, fixed or contingent, accrued or unaccrued, liquidated or unliquidated, asserted or unasserted) of the Sellers and any Affiliate thereof other than the Assumed Liabilities (such liabilities and obligations other than Assumed Liabilities, the “Excluded Liabilities”). Without limiting the foregoing, BH and the Purchaser do not (nor do any of their Affiliates) assume or agree to pay, perform or otherwise discharge the liabilities or obligations (whether known or unknown, fixed or contingent, accrued or unaccrued, liquidated or unliquidated, asserted or unasserted) of the Sellers or their Affiliates with respect to, arising out of or relating to, the following Excluded Liabilities:
(a) except as expressly set forth in Sections 1.3(d) and 1.3(e), and other than the Cure Costs, any liability arising out of facts or circumstances in existence prior to the Closing and from or related to any breach, default under, failure to perform, torts related to the performance of, violations of Law, infringements or indemnities under, guaranties pursuant to and overcharges, underpayments or penalties on the part of the Sellers or any of their Affiliates under any Contract, agreement, arrangement or understanding to which any Seller or any of its Affiliates is a party prior to the Closing;
(b) other than the Cure Costs, any liability arising from or related to any Action against any Seller or its Affiliates, or related to the Business, the Acquired Assets or the Assumed Liabilities, pending or threatened or based on facts, actions, omissions, circumstances or conditions existing, occurring or accruing prior to the Closing Date even if instituted after the Closing Date;
(c) except as set forth in Sections 1.3(b), 1.3(c), 1.3(d) and 1.3(e), any liability arising from or related to the operation of the Business or any of the Sellers’ products or services, or the operation or condition of the Acquired Assets or the Assumed Liabilities prior to the Closing or facts, actions, omissions, circumstances or conditions existing, occurring or accruing prior to the Closing;
(d) all Indebtedness of the Sellers (other than obligations with respect to capitalized leases that are Assigned Contracts);
(e) all guarantees of third-party Indebtedness made by the Sellers and reimbursement obligations to guarantors of the Sellers’ obligations or under letters of credit or other similar agreements or instruments;
(f) all liabilities or obligations arising out of or related to the matters set forth on Section 1.4(f) of the Seller Disclosure Schedule;
(g) all liabilities or obligations to any current or former owner of capital stock or other equity interests of the Sellers or any securities convertible into, exchangeable or exercisable for shares of capital stock or other equity interests of the Sellers, any current or former holder of indebtedness for borrowed money of the Sellers or, in respect of obligations for indemnification or advancement of expenses, any current or former officer or director of the Sellers;
(h) all drafts or checks outstanding at the Closing under which the Sellers are
obligated;
(i) all liabilities or obligations of the Sellers under futures contracts, options on futures, swap agreements or forward sale agreements;
(j) all liabilities for or in respect of Excluded Taxes;
(k) all liabilities and obligations relating to (i) the Benefit Plans (whether arising prior to, on or after the Closing Date) or (ii) the employment or termination of any current or former employee of the Sellers (including any Transferred Employees), and including any current, threatened or potential claims for compensation or benefits, in each such case, to the extent related to employment with the Sellers or termination thereof, whether arising prior to, on or after the Closing Date;
(l) all fees, charges, expenditures, expenses, costs and other payments incurred or otherwise payable by any of the Sellers or their respective affiliates, or for which any of the Sellers or their respective affiliates is liable, in connection with in connection with the administration of the Chapter 11 Case or the negotiation, execution and consummation of the transactions contemplated by this Agreement or any Ancillary Document (including any preparation for a transaction process, bankruptcy process, any sale process involving other potential buyers or any contemplated public offering or financing), including the fees and expenses of financial advisors, accountants, legal counsel, consultants, brokers and other advisors with respect thereto, whether incurred, accrued or payable on or prior to or after the date of this Agreement or the Closing Date;
(m) all liabilities or obligations to the extent relating to the ownership, possession or use of the Excluded Assets;
(n) all liabilities or obligations (x) under Environmental Laws to the extent relating to (i) facts, actions, omissions, circumstances or conditions existing, occurring or accruing, or noncompliance with or violations of Environmental Laws by the Sellers, on or before the Closing Date, (ii) the transportation, off-site storage or off-site disposal of any Hazardous Substances generated by or on behalf of the Sellers on or before the Closing Date or (iii) real property not acquired under this Agreement, including any real property formerly owned, operated or leased by Sellers prior to the Closing Date and (y) for toxic torts arising as a result of or in connection with loss of life or injury to Persons (whether or not such loss or injury was made manifest on or after the Closing Date);
(o) any liability relating to any Product that is or has been manufactured, tested, distributed, held or marketed by or on behalf of any Seller arising from any recall, withdrawal or suspension (whether voluntarily or otherwise), except to the extent that such recall, withdrawal or suspension results from Purchaser’s operation of the Business or the Acquired Assets following the Closing; and
(p) all intercompany accounts payable, liabilities and obligations that are owed or payable to any Seller as to which any Seller is an obligor or is otherwise responsible or liable.

Section 1.5. Assignment of Assigned Contracts.
(a) Section 1.5(a) of the Seller Disclosure Schedule sets forth with respect to each Contract of the Sellers, the Sellers’ good-faith estimate of the amount required to be paid with respect to each Contract to cure all monetary defaults under such Contract to the extent required by Section 365(b) and otherwise satisfy all requirements imposed by Section 365(d) of the Bankruptcy Code (the actual amount of such costs with respect to the Assigned Contracts, the “Cure Costs”). Prior to the Sale Hearing, the Sellers shall commence appropriate proceedings before the Bankruptcy Court and otherwise take all reasonably necessary actions in order to determine the Cure Costs with respect to any Assigned Contract entered into prior to the Petition Date, including, the right (subject to Section 5.1 hereof) to negotiate in good faith and litigate, if necessary, with any Contract counterparty the Cure Costs needed to cure all monetary defaults under such Assigned Contract. Notwithstanding the foregoing, prior to the Designation Deadline, the Purchaser may identify any Assigned Contract that the Purchaser no longer desires to have assigned to it in accordance with Section 1.5(e).
(b) To the maximum extent permitted by the Bankruptcy Code and subject to the other provisions of this Section 1.5, on the Closing Date, the Sellers shall assign the Assigned Contracts pursuant to Section 365 of the Bankruptcy Code and the Sale Order, subject to the provision of adequate assurance by the Purchaser as may be required under Section 365 of the Bankruptcy Code and payment by the Purchaser of the Cure Costs, in respect of the Assigned Contracts.
(c) To the maximum extent permitted by the Bankruptcy Code and subject to the other provisions of this Section 1.5, the Sellers shall assume and transfer and assign all of the Acquired Assets to the Purchaser and the Purchaser shall assume all of the Acquired Assets from the Sellers, as of the Closing Date, pursuant to Sections 363 and 365 of the Bankruptcy Code. Notwithstanding any other provision of this Agreement or in any Ancillary Document to the contrary, this Agreement shall not constitute an agreement to assign any asset or any right thereunder if an attempted assignment without the consent of a third party, which consent has not been obtained prior to the Closing (after giving effect to the Sale Order and the Bankruptcy Code), would constitute a breach or in any way adversely affect the rights of the Purchaser or the Sellers thereunder.
(d) Notwithstanding anything in this Agreement to the contrary, to the extent that the sale, transfer, assignment, conveyance or delivery or attempted sale, transfer, assignment, conveyance or delivery to the Purchaser of any asset that would be an Acquired Asset or any claim or right or any benefit arising thereunder or resulting therefrom is prohibited by any applicable Law or would require any consent from any Governmental Entity or any other third party and such consents shall not have been obtained prior to the Closing (after giving effect to the Sale Order and the Bankruptcy Code), the Closing shall proceed without any reduction in Purchase Price without the sale, transfer, assignment, conveyance or delivery of such asset unless there is a failure of one or more of the conditions set forth in Article VI; in which case, the Closing shall proceed only if each failed condition is waived by the party entitled to the benefit thereof. In the event that any failed condition is waived and the Closing proceeds without the transfer or assignment of any such asset, then following the Closing, each of the Purchaser and each of the Sellers shall use its reasonable best efforts, subject to any approval of the Bankruptcy Court that may be required, and shall cooperate with the other parties, to obtain such consent as promptly as practicable following the Closing. Pending the receipt of such consent, the parties shall, subject to any approval of the Bankruptcy Court that may be required, reasonably cooperate with each other to provide the Purchaser with all of the benefits of use of such asset. Once consent for the sale, transfer, assignment, conveyance or delivery of any such asset not sold, transferred, assigned, conveyed or delivered at the Closing is obtained, the Sellers shall promptly transfer, assign, convey and deliver such asset to the Purchaser. To the extent that any such asset cannot be transferred or the full benefits or use of any such asset cannot be provided to the Purchaser, then as promptly as practicable following the Closing, the Purchaser and the Sellers shall enter into such arrangements (including subleasing, sublicensing or subcontracting), and shall reasonably cooperate with each other to provide the Purchaser with all of the benefits of use of such asset. The Sellers shall hold in trust for, and pay to the Purchaser, promptly upon receipt thereof, all income, proceeds and other monies received by the Sellers derived from their use of any asset that would be an Acquired Asset in connection with the arrangements under this Section 1.5(d). The parties agree to treat any asset the benefits of which are transferred pursuant to this Section 1.5(d) as having been sold to Purchaser for Tax purposes to the extent permitted by Law. Each of the Sellers and Purchaser agrees to notify the other parties promptly in writing if it determines that such treatment (to the extent consistent with the relevant arrangement agreed to by such Seller and Purchaser pursuant to this Section 1.5(d)) is not permitted for Tax purposes under applicable Law. Where such treatment is not so permitted, and subject to the terms of any relevant arrangement agreed to by Sellers and Purchaser pursuant to this Section 1.5(d) (and without duplication of any such Taxes economically borne by Purchaser or any of its Affiliates pursuant thereto), Purchaser shall indemnify and hold harmless the applicable Seller for any Taxes imposed on such Seller or any of its Affiliates with respect to any such Acquired Asset for any Post-Closing Tax Period (determined on a “with and without” basis).
(e) Notwithstanding anything in this Agreement to the contrary, the Purchaser may, in its sole and absolute discretion, amend or revise Section 1.1(c) of the Seller Disclosure Schedule setting forth the Assigned Contracts, in order to add any Contract to, or eliminate any Contract from, such schedule at any time during the period commencing from the date hereof and ending at the end of the Auction (or if no Auction occurs, the date that is two (2) Business Days before the commencement of the Sale Hearing) (the “Designation Deadline”). Automatically upon the addition of any Contract to Section 1.1(c) of the Seller Disclosure Schedule, it shall be an Assigned Contract for all purposes of this Agreement. Automatically upon the removal of any Contract from Section 1.1(c) of the Seller Disclosure Schedule it shall be an Excluded Asset for all purposes of this Agreement, and no liabilities arising thereunder shall be assumed or borne by the Purchaser.

Section 1.6. Purchase Price; Deposit Funds.
(a) In consideration for the Acquired Assets, the Purchaser shall, in addition to the assumption of the Assumed Liabilities by the Purchaser, pay the following amounts (the “Purchase Price”):
(i) (x) one hundred eighty five million five hundred fifty thousand dollars ($185,550,000) in cash, minus (y) the Cure Costs Deduction, minus (z) the GTN Adjustment Amount (the “Cash Consideration”), net of any Deposit Funds paid to the Parent at the Closing pursuant to Section 1.6(b)(i), which Cash Consideration shall be paid to the Parent on behalf of the Sellers at the Closing; and
(ii) an amount in cash (the “Severance Consideration”) to the Parent on behalf of the Sellers equal to the lesser of (x) fourteen million four hundred fifty thousand dollars ($14,450,000) and (y) the amount of severance obligations (inclusive, for the avoidance of doubt, of any payments and benefits in respect of any notice periods under the Worker Adjustment and Retraining Notification Act (and any similar state or local Law) (all such laws collectively, the “WARN Acts”) and any other termination benefits), plus any employer portion of payroll taxes due in respect of such obligations and benefits, that are both (A) payable to any employee of the Sellers who either (1) is an “Eligible Employee” under the severance pay plan of the Parent on the Closing Date and has not received on or before the third (3rd) Business Day following the Auction an offer from BH or its Affiliate for employment commencing on the Closing Date that meets the requirements set forth in Section 5.14, (2) is an “Eligible Employee” under the severance pay plan of the Parent on the Closing Date, is a Relocation Employee and has received, prior to the Closing Date, and rejected (including by not performing services for BH or its Affiliates as of the Closing Date) an offer from BH or its Affiliate for employment commencing on the Closing Date that meets the requirements set forth in Section 5.14 or (3) is a WARN Relocation Employee and has received, prior to the Closing Date, and rejected (including by not performing services for BH or its Affiliates as of the Closing Date) an offer from BH or its Affiliate for employment commencing on the Closing Date that meets the requirements set forth in Section 5.14, and (B) administrative expenses in the Chapter 11 Case pursuant to Sections 503(b)(1) and 507(a)(2) of the Bankruptcy Code; provided, however, that in the event that the Sellers are not authorized to pay severance to employees at the Closing pursuant to the Sale Order, the Purchaser shall instead deposit the Severance Consideration into an escrow account for the benefit of the employees entitled thereto, to be paid to such employees upon the earlier of (X) the Sellers’ emergence from bankruptcy or (Y) Bankruptcy Court approval, with any remaining unused funds being remitted to the Purchaser following payment of all severance obligations.
If the Closing shall occur, at the Closing, the Purchaser and the Parent shall provide joint written instructions, executed by their respective authorized representatives under the Escrow Agreement, to the Escrow Agent that instruct the Escrow Agent to release the Deposit Funds to the Parent on the Closing Date. The Deposit Funds received by the Parent shall be applied at the Closing toward the payment of the Cash Consideration portion of the Purchase Price.
(b) Within three (3) Business Days of the entry of the Bidding Procedures Order, subject to the execution of an escrow agreement reasonably acceptable to the Sellers and the Purchaser (the “Escrow Agreement”), with an escrow agent reasonably acceptable to the Sellers and the Purchaser (the “Escrow Agent”), the Purchaser shall deposit into escrow with the Escrow Agent an amount equal to eighteen million five hundred thousand dollars ($18,500,000) (such amount, together with all interest and other earnings accrued thereon, the “Deposit Funds”), by wire transfer of immediately available funds pursuant to the terms of the Escrow Agreement. The Deposit Funds shall be released by the Escrow Agent and delivered to either (x) the Purchaser or (y) the Parent on behalf of the Sellers, as follows:
(i) if the Closing shall occur, the Deposit Funds shall be applied towards the portion of the Purchase Price payable by Purchaser to the Parent pursuant to Section 1.6(a)(i) hereof;
(ii) if this Agreement is terminated by the Sellers (A) pursuant to Section 7.1(b)(iii) or (B) pursuant to Section 7.1(a) in any circumstance where the Purchaser is not entitled to terminate pursuant to Section 7.1(a) because the failure of the Closing to occur results from the failure of the Purchaser to materially perform its obligations under Section 5.3 required to be performed by it at or prior to the Closing, in each case unless at the time of such termination the Purchaser would have been entitled to terminate this Agreement and has given prior written notice to the Sellers of such claimed right, then the Deposit Funds shall be delivered to the Parent; or
(iii) if this Agreement is terminated other than in a manner provided by Section 1.6(b)(ii), the Deposit Funds shall be delivered to the Purchaser.

[420man]

So you think they are selling basically all their assets to Bausch through BK proceedings and yet still have $83M in cash on hand?

[iDeVos]

What about the $83M of cash/asset reported in the most recent 10-Q filing?
https://www.sec.gov/ix?doc=/Archives/edgar/data/1347613/000134761318000032/sgyp-20180930.htm

just purchased 300K shares today and will added more @ $0.03s/share.

[420man]

Ummm... The asset sale (which is basically everything SGYP has of real value) for $190M to Bausch leaves roughly 11M after liabilities/debts are paid. A good portion of the remaining 11M will be used for BK lawyers and severance packages going forward. What's left of that "may" be disbursed among the Commons...if at all. I'd say they end up with possible $8M in cash after all the dust settles and the the BK judge awards the current OS holders the remainder, which "could" be around .03, but doubtful. JMO

[althegambler]

if that is correct and that judge was aware of that fact he should be excused from the bench. the only reason I can think of that being the case, then you would think it would have to be a vendetta against every stockholder with sgyp stock. lets face it, when the group of stockholders f'd them from getting some bucks, I would imagine they were quite pizzed off. just a thought.

[pauljon4]

They better have a good F'in explanation.

[iDeVos]

I wonder if anyone had read the documents attached along with the doc petitions listed for Synergy case# 18-14010? Below is a copy of the non-binding LOI which indicated BHC willing to acquire the whole Synergy for a total payment package which could valued over $1/share to shareholders (see items iii & iv in the letter: $70M plus a CVR with potential earning up to $250M)

The question now is why Synergy management decided not accepting the offer and in stead selling certain assets to BHC for an amount of the cash more than enough to pay off all the debts and retaining the (shell) company? I guess the decision must be on the facts that whatever left of Synergy is worth more than $1/share, and Synergy management will have to explain in the upcoming hearing on 03/12.

Below is a copy of the text from the letter:
=====================================================================
BAUSCH+ Health
400 Somerset Corporate Boulevard
Bridgewater. New Jersey 08807
908 927 1400
bauschhealth.com

October 13, 2018


Troy Hamilton
Chief Executive Officer
Synergy Pharmaceuticals
420 Lexington Ave #2012
New York, NY 10170

Re: Non-Binding Letter of Intent for the Acquisition of Synergy Pharmaceuticals, Inc.

Dear Troy:
Further to our previous non-binding letter of intent dated August 31, 2018 (the "August LOI") and subsequent conversations between our management teams, Bausch Health Companies Inc. ("Bausch Health") is pleased to present this non-binding letter of intent related to a proposed transaction (the "Transaction") for the acquisition by Bausch Health (and/or one or more of its affiliates) of 100% of the outstanding common stock of Synergy Pharmaceuticals, Inc. (the "Company"). For the avoidance of doubt, this non-binding letter of intent and the terms set forth herein supersede in all respects the August LOI and the terms set forth therein.

Transaction Consideration and Payments at Closing
Based upon our due diligence to date, Bausch Health would be prepared to offer an aggregate purchase price (the "Transaction Consideration") for the outstanding common stock of the Company (including shares of common stock issuable upon the exercise of outstanding options, the exercise of warrants, and the conversion, if any, of the Company's senior convertible notes) and for the repayment of the Company's debt and other obligations, in addition to payments made at Closing for satisfaction of the Company's obligations, consisting of:

(i) up to $165 million in cash paid to the Company to satisfy all of the Company's existmg obligations at the consummation of the Transaction ("Closing") (including repayment of existing debt, severance and retention obligations, and any payments to holders of Company warrants and options);

(ii) up to $34.95 million in cash to be paid to the company's senior secured lender in connection with the prepayment penalty under the Company's senior secured term loan;

(iii) $70 million in cash paid to the company stockholders;

(iv) non-transferable (other than transfers by operation of law (including laws of descent or distribution)) contingent value rights ("CVRs") issuable to the Company's stockholders, which shall expire on the earlier of (a) December 31 of the calendar year in which any generic product competing with TRULANCE becomes available and (b) an outside date (customary for such instruments) to be determined during diligence (such date, the "End Date"), tied to the achievement of the following sales milestones of TRULANCE and Dolcanatide:
Initial milestone achieved in any calendar year after Closing, Aggregate up to and including the End Date: Payment:
$250 million of net sales $40 million
$350 million of net sales $75 million
$500 million of net sales $125 million
$750 million of net sales $200 million
$1 billion of net sales $250 million
$1 .5 billion of net sales $250 million

(v) subject to Bausch Health's diligence on the Company's existing debt, to ensure that the Company has sufficient funds to operate the business in the ordinary course during the period between the signing of the Definitive Agreements (as defined below) and Closing, Bausch Health will make available $30 million for the Company to draw upon between signing and Closing. Beginning 60 days after signing, Bausch Health shall also have the ability to cause the Company to draw down on such funds up to a fixed monthly increment (as an agreed proxy for amounts necessary to fund ongoing Company operations). Any such funds would be provided in the form of a loan (with protections detennined during due diligence). Any portion of such $30 million that remains undrawn as of the Closing (assuming compliance with the interim operating covenants set forth in the Definitive Agreements) will be distributed to the Company's shareholders as part of the Transaction Consideration.
The cash consideration delivered at closing will be funded using Bausch Health's cash on hand.

The Transaction Consideration is based on, among other things, publicly available infom1ation about the Company, the information provided to us to date by and on behalf of the Company and preliminary financial models completed by Bausch Health. Confirmation of the final Transaction Consideration will be dependent on the results of our due diligence.

Due Diligence
It is anticipated that Bausch Health will conduct due diligence on a variety of matters relating to the Company (and its development projects), including, but not limited to, legal, financial, corporate, tax, commercial, manufacturing/supply, regulatory, R&D, intellectual property, employment and labor matters. If it deems it necessary, Bausch Health may request further discussions with the management of the Company and/or a site visit. Bausch Health will expedite its review of the materials and information, with a view to completing its due diligence promptly. However, Bausch Health reserves the right to make
further diligence requests based on the inforn1ation and materials received and discussions conducted in connection with the above-noted items and during the negotiation of the Definitive Agreements.

Definitive Agreements
Bausch Health is prepared to devote the necessary time and resources to negotiate and enter into mutually satisfactory definitive merger agreement, as well as other customary agreements for a transaction of this nature (the "Definitive Agreements"), containing customary terms appropriate to the Transaction, including without limitation appropriate representations, warranties, and covenants of both parties, and to close the Transaction as soon as possible thereafter. We have retained Wachtell, Lipton, Rosen & Katz as legal counsel.

Other Matters
This letter is only a preliminary and non-binding indication of Bausch Health's interest in acquiring the Company and is based on certain assumptions which may change as a result of our due diligence review, negotiations, and other considerations. This letter in not intended to be, and does not, constitute an offer, binding obligation or agreement by Bausch Health to negotiate or enter into a definitive agreement or consummate any transaction involving the Company (or the shares thereof). Furthermore, this letter is not intended, nor shall it be construed, to impose any legal or binding obligation on Bausch Health or the Company or their respective affiliates, and the parties hereto will have no rights or obligations of any kind whatsoever by virtue of this letter or any other written or oral expression by our respective representatives unless and until a definitive agreement is executed and delivered, except in each case, with respect to the confidentiality and exclusivity provisions set forth below.

Confidentiality
This letter is provided to you pursuant to the terms of the Confidentiality Agreement dated January 1 7, 2017, as extended on September 10, 2018, between Bausch Health and the Company and with the understanding that none of the Company, its affiliates, its directors or officers, or any of its or their representatives or advisors, will disclose to any person or entity the terms or existence of this letter, the fact that any investigation, discussions or negotiations are taking place concerning a possible transaction, any other non-public information regarding Bausch Health disclosed to the Company during the negotiations, and the Company agrees to keep such information strictly confidential and will not use any such information for any purpose other than the evaluation of our letter of intent.

Exclusivity
In recognition of the time and resources Bausch Health has devoted and will devote to the evaluation and negotiation of the Transaction, the Company agrees that, for a period commencing on the date hereof and ending upon the earliest of (i) the date of execution of the Definitive Agreements, (ii) termination of negotiations by mutual agreement of the parties hereto, or (iii) 5:00 p.m. Eastern Time on November 30, 2018 (the "Exclusivity Period"), the Company agrees that it will not, and will cause each of its affiliates, and its and their respective directors, officers, employees, partners, managing directors, agents, investment bankers, :financial advisors, attorneys, accountants, agents and representatives (collectively and together with its affiliates, "Representatives"), not to, directly or indirectly: solicit, initiate, facilitate, encourage, accept or enter into discussions or transactions with, or encourage, any corporation, partnership, other entity, individual, entity or group concerning, or provide any information to any of the foregoing in connection with, (a) a merger, consolidation, exchange of shares, recapitalization, liquidation, reorganization, dissolution, business combination or other transaction, (b) any sale, lease or exchange, pledge, transfer or other disposition of 5% or more of the assets of the Company in a single or in multiple transactions or (c) any tender offer, exchange of cash for the securities of the Company, or the acquisition of beneficial ownership of 5% or more of the equity in the Company (each of (a), (b), and (c), an "Acquisition Transaction").

The Company further agrees to, and agrees to cause its Representatives to, cease immediately any and all discussions or negotiations with any person, entity or group other than Bausch Health and its affiliates and their respective representatives, regarding an Acquisition Transaction. The Company agrees to: (i) inform any third party which, during the Exclusivity Period, provides any indication of interest, offer or request for information (that could reasonably be expected to lead to any such offer or indication of interest) in respect of any transaction with the Company that is, or could reasonably be expected to lead to, an Acquisition Transaction (each, an "Unsolicited Bidder Communication") only that it declines to engage in any discussions or negotiations with respect to such Unsolicited Bidder Communication at such time (without disclosing the identity of Bausch Health or the existence or any terms, conditions or other facts of this letter), and (ii) as promptly as practicable (but within 48 hours of receipt), notify Bausch Health if the Company becomes aware of the receipt by the Company or any of its Representatives of any Unsolicited Bidder Communication and of the Company's response thereto in accordance with the immediately preceding clause (i).

Notwithstanding anything to the contrary contained herein, it is expressly agreed that the Company shall be permitted to retain and work with an investment bank during the Exclusivity Period, it being acknowledged that any such investment bank shall be a Representative hereunder and shall be instructed to comply with the terms of the foregoing paragraphs.

Governing Law; Exclusive Jurisdiction
This letter will be governed and construed in accordance with laws of the State of Delaware and the courts of Delaware shall have exclusive jurisdiction.

We are excited about the prospect of this Transaction and we look forward to your favorable response to this letter. Should you have any questions regarding this letter or any information contained in it, please do not hesitate to contact the undersigned.
Very truly yours,

Bausch Health Companies Inc.

[biotech_researcher]

Here is a company that competed with SGYP in the constipation space, Sucampo, SCMP. It had its product out for a number of years ahead of IronWood and of course SGYP. Even though it could be stated that SCMP’s product was inferior to both SGYP and IronWood’s product, that in the end didn’t matter as they had a conservative management team and found a buyer that needed a pipeline..

https://www.bizjournals.com/washington/news/2017/12/26/sucampo-pharmaceuticals-to-be-acquired-in-1-2b.html

[Snackman]

Bausch Health Completes Acquisition Of Certain Assets Of Synergy Pharmaceuticals Inc.
[PR Newswire]
PR Newswire•March 6, 2019

LAVAL, Quebec, March 6, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that the Company has completed the acquisition of certain assets of Synergy Pharmaceuticals Inc. (SGYP) ("Synergy") for a cash purchase price of approximately $195 million and the assumption of certain assumed liabilities, pursuant to the terms of the stalking horse asset purchase agreement previously entered into with Synergy and following approval by the U.S. Bankruptcy Court for the Southern District of New York (the "Bankruptcy Court") on March 1, 2019.

"We are excited to welcome new team members from Synergy to join our Salix Pharmaceuticals business, a leader in gastroenterology. We believe that adding TRULANCE® to our portfolio and dolcanatide to our early pipeline will organically grow this core business for the Company," said Joseph C. Papa, chairman and CEO, Bausch Health. "In 2019, Bausch Health will continue pivoting to offense with research investments and strategic acquisitions and alliances in our core businesses – therapeutic areas that will both drive Company growth and where we can have the biggest impact on the lives of the patients we serve."

Synergy's flagship product, TRULANCE® (plecanatide) is a once-daily tablet approved for adults with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), and its investigational compound, dolcanatide, is an incremental peptide with established proof-of-concept studies in multiple GI conditions.

Wachtell, Lipton, Rosen & Katz served as legal advisor to Bausch Health in this transaction.

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in the Company's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference and the following factors: the possibility that the anticipated benefits of the transaction are not realized when expected or at all, including as a result of the impact of, or problems arising from, the integration of the acquired assets of Synergy; the possibility that the transaction may be more expensive to complete than anticipated; diversion of management's attention from ongoing business operations and opportunities; exposure to potential litigation; and potential adverse reactions or changes to business or employee relationships, including those resulting from the bankruptcy proceedings of Synergy or announcement or completion of the transaction. In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements. The Company believes that the material factors and assumptions reflected in these forward-looking statements are reasonable, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.